RU2019116981A - Композиции и способы лечения желудочно-кишечных полипов - Google Patents
Композиции и способы лечения желудочно-кишечных полипов Download PDFInfo
- Publication number
- RU2019116981A RU2019116981A RU2019116981A RU2019116981A RU2019116981A RU 2019116981 A RU2019116981 A RU 2019116981A RU 2019116981 A RU2019116981 A RU 2019116981A RU 2019116981 A RU2019116981 A RU 2019116981A RU 2019116981 A RU2019116981 A RU 2019116981A
- Authority
- RU
- Russia
- Prior art keywords
- independently
- administration
- polyps
- treatment
- gastrointestinal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/32—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and esterified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
- C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (26)
1. Соединение с формулой
Формула I,
и его фармацевтически приемлемые соли, гидраты, сольваты, пролекарства, энантиомеры и стереоизомеры;
где каждый из R1, R3, R5 независимо представляет собой OD, OCH3, OCOCH3, NULL,
каждый из R2, R4, R6 независимо представляет собой
n независимо равен 1, 2, 3, 4 или 5;
a независимо равен 2, 3 или 7;
каждый b независимо равен 3, 5 или 6;
e независимо равен 1, 2 или 6;
каждый из c и d независимо представляет собой H, D, -OH, -OD, C1-C6-алкил, -NH2 или -COCH3.
2. Фармацевтическая композиция, содержащая соединение по п. 1 и фармацевтически приемлемый носитель.
3. Фармацевтическая композиция по п. 2, которая составлена для лечения лежащей в основе этиологии эффективным количеством, вводимым нуждающемуся пациенту путем перорального введения, отсроченного или замедленного высвобождения, трансмукозального введения, в виде сиропа, местного, парентерального введения, инъекции, подкожного, перорального раствора, ректального введения, трансбуккального введения или трансдермального введения.
4. Соединения и композиции по п. 3, которые составлены для лечения желудочно-кишечных полипов, кишечных полипов и воспаления.
5. Способ лечения по меньшей мере одного из желудочно-кишечных полипов, кишечных полипов и воспалительного заболевания, включающий
введение пациенту, страдающему по меньшей мере одним из желудочно-кишечных полипов, кишечных полипов и воспалительного заболевания, соединения с формулой I
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641038684 | 2016-11-11 | ||
IN201641038684 | 2016-11-11 | ||
PCT/IB2017/052241 WO2018087605A1 (en) | 2016-11-11 | 2017-04-19 | Compositions and methods for the treatment of gastrointestinal polyps |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021114030A Division RU2021114030A (ru) | 2017-04-19 | 2017-04-19 | Композиции и способы лечения желудочно-кишечных полипов |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019116981A3 RU2019116981A3 (ru) | 2020-11-30 |
RU2019116981A true RU2019116981A (ru) | 2020-11-30 |
RU2749188C2 RU2749188C2 (ru) | 2021-06-07 |
Family
ID=62109214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019116981A RU2749188C2 (ru) | 2016-11-11 | 2017-04-19 | Композиции и способы лечения желудочно-кишечных полипов |
Country Status (14)
Country | Link |
---|---|
US (2) | US11225464B2 (ru) |
EP (1) | EP3538086A4 (ru) |
JP (1) | JP7118449B2 (ru) |
KR (1) | KR102408871B1 (ru) |
CN (1) | CN110167548A (ru) |
AU (1) | AU2017357873B2 (ru) |
BR (1) | BR112019009615A2 (ru) |
CA (1) | CA3043445C (ru) |
IL (1) | IL266545B (ru) |
MX (1) | MX2019005568A (ru) |
RU (1) | RU2749188C2 (ru) |
SG (1) | SG10202104160TA (ru) |
WO (1) | WO2018087605A1 (ru) |
ZA (1) | ZA201903222B (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017357873B2 (en) * | 2016-11-11 | 2022-02-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of gastrointestinal polyps |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602910B2 (en) * | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
US20140287004A1 (en) * | 2005-11-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs |
CA2672513C (en) * | 2007-02-15 | 2010-05-25 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
EP2650279A3 (en) * | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
PL387312A1 (pl) * | 2009-02-19 | 2010-08-30 | Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi |
US8207363B2 (en) * | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
EP2560634A1 (en) * | 2010-04-23 | 2013-02-27 | Piramal Enterprises Limited | Nitric oxide releasing prodrugs of therapeutic agents |
ES2602075T3 (es) * | 2011-10-31 | 2017-02-17 | Larsen, Claus Selch | Profármacos de agentes antiinflamatorios no esteroideos (AINE) |
WO2014068461A2 (en) * | 2012-11-02 | 2014-05-08 | Mahesh Kandula | Compositions and methods for the treatment of acute inflammation |
CA2967908C (en) * | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
AU2017357873B2 (en) * | 2016-11-11 | 2022-02-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of gastrointestinal polyps |
-
2017
- 2017-04-19 AU AU2017357873A patent/AU2017357873B2/en active Active
- 2017-04-19 SG SG10202104160TA patent/SG10202104160TA/en unknown
- 2017-04-19 BR BR112019009615A patent/BR112019009615A2/pt not_active IP Right Cessation
- 2017-04-19 KR KR1020197016008A patent/KR102408871B1/ko active IP Right Grant
- 2017-04-19 EP EP17869375.0A patent/EP3538086A4/en not_active Withdrawn
- 2017-04-19 CA CA3043445A patent/CA3043445C/en active Active
- 2017-04-19 JP JP2019547199A patent/JP7118449B2/ja active Active
- 2017-04-19 RU RU2019116981A patent/RU2749188C2/ru active
- 2017-04-19 WO PCT/IB2017/052241 patent/WO2018087605A1/en unknown
- 2017-04-19 US US16/348,954 patent/US11225464B2/en active Active
- 2017-04-19 MX MX2019005568A patent/MX2019005568A/es unknown
- 2017-04-19 CN CN201780083005.7A patent/CN110167548A/zh active Pending
-
2019
- 2019-05-09 IL IL266545A patent/IL266545B/en unknown
- 2019-05-22 ZA ZA2019/03222A patent/ZA201903222B/en unknown
-
2021
- 2021-12-02 US US17/457,398 patent/US20220162171A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11225464B2 (en) | 2022-01-18 |
CA3043445A1 (en) | 2018-05-17 |
EP3538086A4 (en) | 2021-01-20 |
KR20190100178A (ko) | 2019-08-28 |
MX2019005568A (es) | 2019-09-27 |
CN110167548A (zh) | 2019-08-23 |
IL266545B (en) | 2021-10-31 |
WO2018087605A1 (en) | 2018-05-17 |
KR102408871B1 (ko) | 2022-06-15 |
JP7118449B2 (ja) | 2022-08-16 |
CA3043445C (en) | 2023-08-22 |
BR112019009615A2 (pt) | 2019-08-13 |
RU2019116981A3 (ru) | 2020-11-30 |
EP3538086A1 (en) | 2019-09-18 |
NZ753702A (en) | 2022-03-25 |
US20200190040A1 (en) | 2020-06-18 |
AU2017357873A1 (en) | 2019-06-06 |
IL266545A (en) | 2019-07-31 |
JP2019535824A (ja) | 2019-12-12 |
US20220162171A1 (en) | 2022-05-26 |
AU2017357873B2 (en) | 2022-02-24 |
ZA201903222B (en) | 2021-08-25 |
SG10202104160TA (en) | 2021-06-29 |
RU2749188C2 (ru) | 2021-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018135343A5 (ru) | ||
JP2009143956A5 (ru) | ||
CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
RU2010126056A (ru) | Органические соединения | |
JP2015518880A5 (ru) | ||
WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
RU2016118399A (ru) | Производные 4-аминометилбензойной кислоты | |
JP2016531126A5 (ru) | ||
RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
RU2019116981A (ru) | Композиции и способы лечения желудочно-кишечных полипов | |
RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
JP2015520770A5 (ru) | ||
RU2013108944A (ru) | Ингибиторы faah периферически-ограниченного действия | |
WO2013175376A3 (en) | Compositions and methods for the treatment of local pain | |
RU2019100713A (ru) | Композиции и способы для лечения рака | |
JPWO2020260252A5 (ru) | ||
JP2017523141A5 (ru) | ||
RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
JP2010505869A5 (ru) |